此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

急性髓系白血病患者 CD371-YSNVZIL-18 CAR T 细胞的研究

2026年10月5日 更新者:Memorial Sloan Kettering Cancer Center

CLEc12a (CD371) 靶向 ArmoRed 免疫效应细胞治疗复发/难治性急性髓系白血病 (CLEAR-AML) 患者的 I 期试验

The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

研究概览

研究类型

介入性

注册 (估计的)

15

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Monmouth (Limited protocol activities)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center (All protocol activites)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745
      • Rockville Centre、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau (Limited Protocol Activites)
        • 接触:
          • Mark Geyer, MD
          • 电话号码:646-608-3745

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Subject Inclusion: Collection of T cells (Part A)

  • History of CD371+ AML

    • Any disease status is eligible for collection
    • Expression of CD371 at any level on AML blasts (any method of detection including IHC and/or flow cytometry)
  • Age/Weight

    • Pediatrics: ≥ 1 year and ≥ 10kg for collection for dose levels, 1, 2, and -1
    • ≥ 12 years and ≥ 40 kg for collection for dose level 1A.
    • Adults: no limit on age/weight for collection for dose levels 1, 2, and -1.
    • ≥ 40 kg for collection for dose level 1A.
  • Patients with history of allo-HCT are eligible for collection if:

    • ≥ 100 days post-transplant however, as noted in Section 6.1.2, patients must be ≥180 days post-transplant to be eligible for treatment
    • no evidence of active GVHD
    • off any immunosuppressive agents for 30 days prior to collection (physiologic dose of corticosteroids is acceptable)

Subject Inclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)

  • Relapsed/Refractory CD371+ AML (meeting criteria defined below) for primary refractory AML, late first relapse, and/or advanced disease:

    o Primary refractory AML: Patients are eligible from disease perspective in the event of failure to achieve a CR, CRh or CRi after one or more of the following regimens:

  • Two or more courses of standard intensive induction chemotherapy (e.g., cytarabine and daunorubicin given as "7+3," MEC, HiDAC, FLAG+idarubicin, etc.);

  • Two or more cycles of venetoclax in combination with one of the following (azacitidine OR decitabine OR low-dose cytarabine), with or without other agents;

  • Six or more cycles of azacitidine monotherapy OR four or more courses of decitabine monotherapy

    • Early first relapse: Patients are eligible from disease perspective in the event of first morphologic relapse or new extramedullary disease less than 12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy
    • Late first relapse: Patients with first morphologic relapse or new extramedullary disease ≥12 months after previously having achieved CR, CRh, or CRi following AML-directed therapy may respond to intensive re-induction using the initial induction regimen and not eligible from a disease perspective unless the treating investigator feels the patient is unlikely to benefit from repeating the initial induction regimen (for example, relapse occurring 12 months into CR on continuous azacitidine/venetoclax therapy), in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient.
    • Advanced disease: Patients are eligible from disease perspective in the event of relapsed AML refractory to reinduction therapy, relapse following alloHCT, or second or later relapse.
    • Disease eligibility considerations for all patients: Patients with relapsed or refractory AML with susceptible mutations for which there is an FDA approved therapy (for example, IDH1 mutation, ivosidenib; IDH2 mutation, enasidenib; FLT3-ITD/TKD, gilteritinib) are not eligible from a disease perspective unless they meet one or more of the below criteria:
  • Failure to achieve CR, CRh, or CRi following therapy with one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);

  • Intolerance of one or more targeted therapies for relapsed or refractory AML directed to the actionable mutation(s);

  • Treating investigator feels the patient would be unlikely to benefit from FDA-approved targeted therapy based on disease characteristics, in which case the rationale for considering enrollment must be clearly documented and risks, benefits, and alternatives discussed with the patient Age: any age is eligible for treatment if eligible for collection

    o The first 3 patients in the first dose cohort must be ≥ 16 years of age, while the first 2 patients in subsequent cohorts must be ≥ 16 years of age (see Section 10.4) . Nopatient enrolled to dose level 1A shall be <12 years of age (and first 2 patients must be ≥ 16 years of age).

  • Adequate performance status:

    • Age ≥ 16 years: ECOG ≤ 1 or Karnosfsky ≥ 60
    • Age < 16 years: Lansky ≥ 60
  • Patients with history of allo-HCT are eligible for treatment if:

    • ≥ 180 days post-transplant
    • no evidence of active GVHD
    • off any systemic immunosuppressive agents for 30 days prior to treatment (physiologic dose of corticosteroids is acceptable)
    • Treating physician considers the patient to be a candidate for second alloHCT
  • Identification of a suitable donor/source for alloHCT as determined by the treating physician.

  • Adequate organ function is required, defined as follows:

    • Hepatic: Serum total bilirubin ≤ 1.5 mg/dL, unless benign congenital hyperbilirubinemia or unless thought to be disease related.
    • Hepatic: ALT and AST < 3 times the upper limit of normal unless thought to be disease-related.
    • Renal: serum creatinine < 2.0 mg/100 ml (> 18 years) or ≤ 2.5 x institutional upper limit of normal (ULN) for age
  • If serum creatinine is outside the normal range, then CrCl > 40 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.73m2) > 40% of predicted normal for age.

Normal GFR by Age Age: 1 week / Mean GFR +/-SD (mL/min/1.73 m2): 40.6 + / - 14.8 Age: 2 - 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 65.8 + / - 24.8 Age: > 8 weeks / Mean GFR +/-SD (mL/min/1.73 m2): 95.7 +/- 21.7 Age: 2 - 12 years / Mean GFR +/-SD (mL/min/1.73 m2): 133 +/- 27 Age: 13 - 21 years (males) / Mean GFR +/-SD (mL/min/1.73 m2): 140 +/- 30 Age: 13 - 21 years (females) / Mean GFR +/-SD (mL/min/1.73 m2): 126.0 + / - 22.0 Abbreviations: GFR, glomerular f filtration rate; SD, standard deviation

  • Greater than 2 years old: Normal GFR is 100 mL/min/1.73m2.

  • Infants: GFR must be corrected for body surface area.

    • Cardiac: LVEF ≥ 50% by MUGA or resting echocardiogram.
    • Pulmonary: Adequate pulmonary function as assessed by ≥ 92% oxygen saturation on room air by pulse oximetry

Exclusion Criteria:

Subject Exclusion: Collection of T cells (Part A)

  • Pregnant or lactating women; women of childbearing age, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception while receiving study treatment and for at least 12 months after all treatment is finished

  • Sexually active males, unless they are willing to use a condom during intercourse while receiving study treatment and for at least 12 months after all treatment is finished

  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.

  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject

  • Impaired cardiac function (LVEF < 50%) as assessed by ECHO or MUGA scan

  • Patients with following cardiac conditions will be excluded:

    • New York Heart Association (NYHA) stage III or IV congestive heart failure
    • Myocardial infarction ≤ 6 months prior to enrollment
    • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for HIV

  • Acute or chronic HBV infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.

  • Acute or chronic HCV infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR

  • Patient/parent/LAR unable to give informed consent/

Subject Exclusion: Treatment with CD371-specific/YSNVz/IL-18 CAR T cells (Part B)

  • Bridging chemotherapy occurring < 1 week prior to administration of LDC

    o Exception: hydroxyurea can be continued up to 72 hours prior to leukapheresis or 24 hours prior to LDC

  • Pregnant or lactating women

  • Radiographically-detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥ 5/ul WBC in CSF). Subjects with adequately treated CNS leukemia are eligible.

  • Isolated extramedullary disease

  • Lack of a suitable donor/source for allogeneic HSCT as determined by the treating physician.

  • Patients with prior alloHCT are allowed as long as alloHCT occurred ≥100 days prior to date of treatment with CD371-specific/YSNVz/IL-18 CAR T cells and as long as the patient is without ongoing requirement for systemic graft-versus-host therapy

  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject

  • Impaired cardiac function (LVEF < 50%) as assessed by ECHO or MUGA scan.

  • Patients with following cardiac conditions will be excluded:

    • New York Heart Association (NYHA) stage III or IV congestive heart failure
    • Myocardial infarction ≤ 6 months prior to enrollment
    • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
  • Positive serologic test results for HIV.

  • Acute or chronic HBV infection as assessed by serologic (HBVsAg) or PCR results, defined as HBVsAg+, HBVcAb+, HBV PCR+.

  • Acute or chronic HCV infection as assessed by serologic (HCV ab) or PCR results, defined as HCV Ab+ with reflex to positive HCV PCR

  • Active second malignancy that requires systemic treatments, with the exception of malignancy treated with curative intent and without evidence of disease for > 2 years before screening

  • Patient/parent/LAR unable to give informed consent

  • Any other condition/issue which, in the opinion of the treating physician, would make the patient ineligible for the study; conditions that in the Principal Investigator's opinion might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Level 1

Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

实验性的:Dose Level 2

Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

实验性的:Step-Down Dose

Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Tolerated Dose (MTD) of CAR T cells
大体时间:up to 6 months

Determine the Maximum Tolerated Dose/MTD of CAR T cells in participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mark Geyer, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年9月1日

初级完成 (估计的)

2027年12月17日

研究完成 (估计的)

2027年12月17日

研究注册日期

首次提交

2023年8月24日

首先提交符合 QC 标准的

2023年8月24日

首次发布 (实际的)

2023年8月30日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅